Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals

Home/Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals

Regulation & Policy (Pharma & Healthcare), Finance & Investment (Pharma & Healthcare), Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare

Publication ID:

GDA0316676

Publication Date:

March 01, 2016

Pages:

108

Publisher:

GlobalData

Region:

Global

$1,000.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals

Summary

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for January 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in January 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, January 2016 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, January 2016 14
2.2.1 Shire to Acquire Baxalta for USD32 Billion 14
2.2.2 Abbott Labs to Acquire Alere 16
2.2.3 Nestle Health Science Enters into Licensing Agreement with Seres Therapeutics 17
2.2.4 Nanjing Xinjiekou to Acquire 65% Stake in China Cord Blood from Golden Meditech for USD883 Million 18
2.2.5 Sanofi Enters into Licensing Agreement with Warp Drive Bio 19
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, January 2016 21
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, January 2016 22
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 23
3.1 Pharmaceuticals & Healthcare, Global, M&A, January 2016 23
3.1.1 Top M&A Deals in January 2016 24
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, August 2015 - January 2016 25
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, January 2016 27
3.2.1 Top Equity Offering Deals in January 2016 28
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, August 2015 - January 2016 29
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, January 2016 31
3.3.1 Top PE/VC Deals in January 2016 32
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, January 2016 33
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, January 2016 34
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2015-January 2016 36
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2015-January 2016 37
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2016 38
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, January 2016 38
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, August 2015 - January 2016 40
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), January 2016 42
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, January 2016 43
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 44
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, August 2015 - January 2016 46
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), August 2015 - January 2016 47
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 49
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2016 51
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, January 2016 51
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), January 2016 53
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), August 2015 - January 2016 55
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), August 2015 - January 2016 57
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), August 2015 - January 2016 59
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), August 2015 - January 2016 62
5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, January 2016 63
5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, January 2016 64
5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, January 2016 65
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 66
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, January 2016 66
6.1.1 Oncology - Deals of the Month 67
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, January 2016 69
6.2.1 Central Nervous System - Deals of the Month 71
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, January 2016 72
6.3.1 Infectious Diseases - Deals of the Month 74
6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, January 2016 76
6.4.1 Cardiovascular - Deals of the Month 78
6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, January 2016 79
6.5.1 Immunology - Deals of the Month 81
6.6 Pharmaceuticals & Healthcare, Global, Respiratory Deals, January 2016 82
6.6.1 Respiratory - Deal of the Month 84
6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, January 2016 85
6.7.1 Metabolic Disorders - Deal of the Month 86
7 Deal Summary by Geography 87
7.1 Pharmaceuticals & Healthcare, North America Deals, January 2016 87
7.1.1 North America - Deals of the Month 88
7.2 Pharmaceuticals & Healthcare, Europe, Deals, January 2016 91
7.2.1 Europe - Deals of the Month 93
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, January 2016 96
7.3.1 Asia-Pacific - Deals of the Month 97
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, January 2016 98
7.4.1 Rest of the World - Deals of the Month 99
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 101
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, August 2015 - January 2016 101
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, August 2015 - January 2016 103
9 Further Information 105
9.1 Methodology 105
9.2 About GlobalData 106
9.3 Disclosure information 107
9.4 Disclaimer 107

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, January 2016 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), January 2016 22
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 24
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, January 2016 24
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2015 - January 2016 26
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 28
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, January 2016 28
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 30
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 32
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, January 2016 32
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, August 2015 - January 2016 34
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), January 2016 35
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 36
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2015 - January 2016 37
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 39
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 41
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 42
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), January 2016 43
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 45
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2015 - January 2016 48
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), August 2015 - January 2016 50
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 52
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 54
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 56
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), January 2016 58
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2015 - January 2016 61
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), January 2016 63
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, January 2016 63
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, January 2016 64
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, January 2016 65
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 67
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 70
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 73
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 77
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 80
Table 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 83
Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 86
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 88
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 92
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 97
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 99
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 102
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 104

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), January 2016 21
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), January 2016 22
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 23
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2015 - January 2016 25
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 27
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 29
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 31
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, August 2015 - January 2016 33
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), January 2016 34
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), January 2016 35
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 36
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 38
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 40
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 42
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 44
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2015 - January 2016 46
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, August 2015 - January 2016 47
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 49
Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 51
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 53
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), August 2015 - January 2016 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, August 2015 - January 2016 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), August 2015 - January 2016 60
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), January 2016 62
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 66
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 69
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 72
Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 76
Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 79
Figure 32: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 82
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 85
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 87
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 91
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 96
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 98
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 101
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), August 2015 - January 2016 103

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".